Skip to main content

Advertisement

SpringerLink
Log in

Systemischer Effekt einer lokalen Strahlentherapie: erste klinische Evidenz

Systemic effects of local radiotherapy: first clinical evidence

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Twyman-Saint Victor C et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377

    Article  CAS  Google Scholar 

  2. Postow MA et al (2012) Immunologic correlates of the Abscopal effect in a patient with melanoma. N Engl J Med 366:925–931

    Article  CAS  Google Scholar 

  3. Formenti SC et al (2018) Radiotherapy induces responses of lung cancer to CTLA‑4 blockade. Nat Med 24:1845

    Article  CAS  Google Scholar 

  4. Garon EB et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

    Article  Google Scholar 

  5. Brahmer J et al (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

    Article  CAS  Google Scholar 

  6. Borghaei H et al (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

    Article  CAS  Google Scholar 

  7. Theelen WSME et al (2019) Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 5:1276–1282

    Article  Google Scholar 

  8. Welsh J et al (2020) Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. https://doi.org/10.1136/jitc-2020-001001

    Article  PubMed  PubMed Central  Google Scholar 

  9. Basler L, Andratschke N, Ehrbar S, Guckenberger M, Tanadini-Lang S (2018) Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study. Radiat Oncol 13:10

    Article  CAS  Google Scholar 

  10. McBride S et al (2020) Randomized phase II trial of Nivolumab with stereotactic body radiotherapy versus Nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol. https://doi.org/10.1200/JCO.20.00290

    Article  PubMed  Google Scholar 

  11. Gandhi L et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092

    Article  CAS  Google Scholar 

  12. Socinski MA et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–2301

    Article  CAS  Google Scholar 

  13. Hellmann MD et al (2018) Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093–2104

    Article  CAS  Google Scholar 

  14. Paz-Ares L et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30641-0

    Article  PubMed  Google Scholar 

  15. Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52:17–35

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Radio-Onkologie, UniversitätsSpital Zürich, Universität Zürich, Raemistrasse 100, 8091, Zürich, Schweiz

    Matthias Guckenberger MD

Authors
  1. Matthias Guckenberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Guckenberger MD.

Ethics declarations

Interessenkonflikt

M. Guckenberger gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV et al (2020) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. October https://doi.org/10.1016/S2213-2600(20)30391-X.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guckenberger, M. Systemischer Effekt einer lokalen Strahlentherapie: erste klinische Evidenz. Strahlenther Onkol 197, 458–460 (2021). https://doi.org/10.1007/s00066-021-01752-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-021-01752-x

Search

Navigation